Lixisenatide

BreastfeedingPediatric
  • TRADE NAMES: Adlyxin (Sanofi-Aventis); Lyxumia (Sanofi-Aventis); Soliqua (Sanofi-Aventis)
  • INDICATIONS: To improve glycemic control in adults with Type II diabetes mellitus
  • CLASS: Glucagon-like peptide-1 (GLP-1) receptor agonist
  • HALF-LIFE: 3 hours

FDA APPROVAL DATE: 07/27/2016

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus

Soliqua is lixisenatide and insulin glargine.

Our database has 23 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
LOCAL.
RESPIRATORY.
OTHER.


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top